Results 91 to 100 of about 1,395,322 (291)

Optimal duration of magazine promotions [PDF]

open access: yes, 2004
The planning of promotions and other marketing events frequently requires manufacturers to make decisions about the optimal duration of these activities. Yet manufacturers often lack the support tools for decision making.
Esteban-Bravo, Mercedes   +2 more
core   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

open access: yesMolecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck   +12 more
wiley   +1 more source

UKRAINE IN THE CONTEXT OF WORLD BOOK PUBLISHING

open access: yesІнтегровані комунікації
The publishing industry of the world’s developed countries is not only an important component of ideo- logical, political, and cultural influence on society but also a significant part of filling the state treasury. The purpose of the proposed article is
Viktor Shpak
doaj   +1 more source

Technology: Friend or Foe to the Publishing Industry [PDF]

open access: yes, 2009
In recent years, publishers, such as Random House and HarperCollins, have been turning to new technologies, such as print-on-demand (POD) and e-ink, to cut costs, to broaden their audiences, and to adapt to the challenging economic climate.
Leal, Kendra Mae
core   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

open access: yesMolecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto   +8 more
wiley   +1 more source

The diamond model of open access publishing: Why policy makers, scholars, universities, libraries, labour unions and the publishing world need to take non-commercial, non-profit open access serious [PDF]

open access: yes, 2013
This reflection introduces a new term to the debate on open access publishing: diamond open access (DOA) publishing. The debate on open access is a debate about the future of academia.
Fuchs, C., Sandoval, M.
core   +3 more sources

Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology

open access: yesMolecular Oncology, EarlyView.
Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...
Marius Ilié   +13 more
wiley   +1 more source

Laying The Foundations: New Beacon Books, Bogle L’Ouverture Press and the Politics of Black British Publishing

open access: yesE-REA, 2013
Drawing on previously unpublished interviews with Sarah White and Eric and Jessica Huntley, this article compares the work of two pioneering black publishing houses in Britain in the latter half of the twentieth century, New Beacon Books and Bogle L ...
Philippa IRELAND
doaj   +1 more source

The Changing Landscape of Scholarly Publishing: Will Radiation Research Survive? [PDF]

open access: yes, 2013
As a society published journal, Radiation Research has been a successful and enduring project of the Radiation Research Society (RRS). In 59 years of publication, the journal has produced 732 issues and 10,712 articles.
Odell, Jere D., Whipple, Elizabeth C.
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy